-
Mayo Clinic Laboratories and Lucence announce strategic collaboration to enhance cancer testing services
Share this:
ROCHESTER, Minn., and PALO ALTO, Calif. — Mayo Clinic Laboratories, a global leader in advanced laboratory testing, and Lucence, a pioneering molecular diagnostics company, announced a strategic collaboration today to expand international access to cutting-edge cancer testing services. This collaboration aims to leverage the strengths of both organizations to drive better outcomes for patients worldwide.
Lucence, with its CLIA-licensed and CAP-accredited laboratories in California and Singapore, will provide access to its innovative LiquidHALLMARK® technology through Mayo Clinic Laboratories. LiquidHALLMARK® is an ultra-sensitive, next-generation sequencing liquid biopsy that analyzes circulating tumor DNA (ctDNA) and circulating tumor RNA (ctRNA) for clinically relevant biomarkers across various cancers.
“We look forward to making LiquidHALLMARK available so physicians and their patients have access to important insights that can inform treatment decisions,” said William Morice, M.D., Ph.D., president and CEO of Mayo Clinic Laboratories. “Incorporating this test into our catalog supports our goal of offering comprehensive testing options for serious or complex cases.”
The Medicare-covered LiquidHALLMARK® test provides actionable findings by offering targeted therapies based on genomic results, including detailed descriptions of each finding and associated clinical trials. The test reports include graphical maps for understanding cancer genomic profiles and tracking tumor changes over time, while delivering comprehensive information on each genomic finding, highlighting its role in the patient’s cancer type and existing functional evidence.
"Working with Mayo Clinic Laboratories will advance our shared goal of making innovative cancer tests available to benefit everyone globally," said Min-Han, M.B.B.S., F.R.C.P., Ph.D., founding CEO and medical director of Lucence. "Combining Lucence's liquid biopsy testing with Mayo Clinic Laboratories' broad reach and expertise means that healthcare providers everywhere can be empowered with important information to improve personalized cancer care."
The collaboration between Mayo Clinic Laboratories and Lucence represents a significant step forward in the field of oncology diagnostics. By integrating their respective strengths, the two organizations aim to provide healthcare providers with the tools they need to make informed decisions and deliver personalized treatment plans for their patients.
Mayo Clinic Laboratories is a for-profit, wholly-owned subsidiary of Mayo Clinic. Therefore, Mayo Clinic has an indirect financial interest in the technology referenced in this press release. Mayo Clinic will use any revenue it receives to support its not-for-profit mission in patient care, education and research.
###
About Mayo Clinic Laboratories
Mayo Clinic Laboratories, the global leader in turning test results into clinical answers, provides advanced testing and pathology services for 3,400 healthcare organizations in partnership with Mayo Clinic's Department of Laboratory Medicine and Pathology. Mayo Clinic Laboratories offers more than 4,400 tests and pathology services and performs more than 26 million tests annually.
About Lucence
Lucence is a precision oncology company committed to improving cancer care through innovative testing solutions. With CLIA-licensed and CAP-accredited laboratories in California and Singapore, Lucence offers advanced liquid biopsy technologies that provide critical insights into cancer biology. The company's flagship product, LiquidHALLMARK®, is designed to detect clinically relevant biomarkers in ctDNA and ctRNA, enabling precise and personalized cancer treatment.
Media contact:
- Mayo Clinic Laboratories: newsbureau@mayo.edu
- Lucence: inquiry@lucence.com
